The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer

被引:0
作者
Yariv, Orly [1 ,2 ]
Mutai, Raz [1 ,2 ]
Rotem, Ofer [1 ,2 ]
Tsoref, Daliah [1 ,2 ]
Korzets, Yasmin [2 ,3 ]
Moore, Assaf [1 ,3 ]
Shochat, Tzippy [4 ]
Yerushalmi, Rinat [1 ,2 ]
Goldvaser, Hadar [5 ,6 ]
机构
[1] Rabin Med Ctr, Inst Oncol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel
[4] Rabin Med Ctr, Statist Consulting Unit, Petah Tiqwa, Israel
[5] Inst Oncol, Shaare Zedek Med Ctr, Jerusalem, Israel
[6] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
关键词
Breast cancer; Estrogen; Oral contraceptive; Hormonal replacement therapy; Fertility treatment; Outcome; Tumor characteristics; HORMONE REPLACEMENT THERAPY; COLLABORATIVE REANALYSIS; ORAL-CONTRACEPTIVES; RISK; WOMEN; COHORT; DRUGS;
D O I
10.1159/000518183
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The impact of exogenous estrogen exposure on breast cancer characteristics and outcomes is not well described. We aimed to investigate the effect of prior treatment with oral contraceptives (OCT), hormone replacement therapy (HRT), and fertility treatments on early-stage, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods: This is a single-center retrospective cohort study comprising all women with ER-positive, HER2-negative, early breast cancer whose tumors were sent to Oncotype DX analysis between 2005 and 2012. Data on prior exposures to OCT, HRT, and fertility treatments were collected. The impact of these exposures on prespecified histopathological features was assessed including tumor size, nodal status, intensity of the hormonal receptors, grade, Oncotype recurrence score, Ki67, and lymphovascular and perineural invasion. The impact of these exposures on disease-free survival (DFS) and overall survival (OS) was also evaluated. Results: A total of 620 women were included, of which 19% had prior exposure to OCT, 30% to HRT, and 11% to fertility treatments. OCT use was associated with smaller (<= 1 cm) tumors (p = 0.023) and were less likely to have grade 3 disease (p = 0.049). No other associations were found between exogenous estrogen exposure and tumor characteristics. Median follow-up was 10.4 years. Ten-year DFS was 85.7%, and it was not influenced by exogenous exposure. Ten-year OS was 90.2%, and OCT was associated with improved OS in univariate analysis (HR = 0.31, 95% CI: 0.11-0.85), but this difference did not remain significant in multivariate analysis (p = 0.275). Conclusion: The impact of exogenous estrogen exposure on ER-positive, HER2-negative early breast cancer characteristics is limited. In the long term, none of the evaluated exposures had negative effect on DFS and OS.
引用
收藏
页码:713 / 721
页数:9
相关论文
共 34 条
[1]   Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].
Bauer, Katrina R. ;
Brown, Monica ;
Cress, Rosemary D. ;
Parise, Carol A. ;
Caggiano, Vincent .
CANCER, 2007, 109 (09) :1721-1728
[2]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[3]   Long-term Relationship of Ovulation-Stimulating Drugs to Breast Cancer Risk [J].
Brinton, Louise A. ;
Scoccia, Bert ;
Moghissi, Kamran S. ;
Westhoff, Carolyn L. ;
Niwa, Shelley ;
Ruggieri, David ;
Trabert, Britton ;
Lamb, Emmet J. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (04) :584-593
[4]   Different menopausal hormone regimens and risk of breast cancer [J].
Brusselaers, N. ;
Tamimi, R. M. ;
Konings, P. ;
Rosner, B. ;
Adami, H. O. ;
Lagergren, J. .
ANNALS OF ONCOLOGY, 2018, 29 (08) :1771-1776
[5]  
Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5
[6]   Hormone replacement therapy in relation to breast cancer [J].
Chen, CL ;
Weiss, NS ;
Newcomb, P ;
Barlow, WN ;
White, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (06) :734-741
[7]   PROGESTERONE RECEPTORS AS A PROGNOSTIC FACTOR IN STAGE-II BREAST-CANCER [J].
CLARK, GM ;
MCGUIRE, WL ;
HUBAY, CA ;
PEARSON, OH ;
MARSHALL, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (22) :1343-1347
[8]   Mechanisms of disease - Estrogen and the risk of breast cancer [J].
Clemons, M ;
Goss, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (04) :276-285
[9]   Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence [J].
Collaborative Group on Hormonal Factors in Breast Cancer .
LANCET, 2019, 394 (10204) :1159-1168
[10]   Breast cancer risk with postmenopausal hormonal treatment [J].
Collins, JA ;
Blake, JM ;
Crosignani, PG .
HUMAN REPRODUCTION UPDATE, 2005, 11 (06) :545-560